BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Compared to chemotherapy, it often has fewer side effects and a better quality of life for patients, more examples, such as imatinib (Gleevec), which is used in treating chronic myeloid leukemia (CML), targets the BCR-ABL tyrosine kinase, which is active in CML cells.